This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMN or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
Here's Why Investors Should Bet on Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) expects 2022 medical customers to grow by a minimum of 725,000, suggesting an upside from the prior projection.
UnitedHealth (UNH) Rewards Shareholders With 13.8% Dividend Hike
by Zacks Equity Research
UnitedHealth's (UNH) strong balance sheet supports its endeavors to return shareholders' funds.
Encompass Health (EHC) Updates 2022 Guidance: Dips 5.4%
by Zacks Equity Research
Encompass Health (EHC) expects to retain its cash dividend routine. However, the amount might decline to reflect the spin-off of the home health and hospice business.
Ensign Group (ENSG) Up 3.7% in 30 Days: More Room to Rally?
by Zacks Equity Research
Ensign Group's (ENSG) rising profits from Skilled Services business are a major positive.
HCA Healthcare's (HCA) Utah Acquisition Faces Fed Roadblocks
by Zacks Equity Research
The trade watchdog expects HCA Healthcare's (HCA) Utah acquisition to induce market concentration and eliminate Steward Health Care as a low-cost competitor.
Implied Volatility Surging for Progyny (PGNY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Progyny (PGNY) stock based on the movements in the options market lately.
AMN vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%
by Zacks Equity Research
The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.
Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 150% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Progyny (PGNY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVTR vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVTR vs. PGNY: Which Stock Is the Better Value Option?
OCDX vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCDX vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 275% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Progyny (PGNY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny (PGNY) Q3 Earnings Beat Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 142.86% and -2.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
by Zacks Equity Research
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
5 Medical Services Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most. However, falling healthcare spending may disrupt the trend.
Progyny (PGNY) Beats Q2 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 111.11% and -0.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny (PGNY) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured highlights include: Digital Turbine, 360 DigiTech, Progyny and E.W. Scripps
by Zacks Equity Research
Zacks.com featured highlights include: Digital Turbine, 360 DigiTech, Progyny and E.W. Scripps